Department of Cardiology, Robert-Bosch-Medical Center, Auerbachstrasse 110, Stuttgart, Germany.
J Am Coll Cardiol. 2012 May 1;59(18):1604-15. doi: 10.1016/j.jacc.2012.01.007. Epub 2012 Feb 22.
This study sought to evaluate the long-term mortality in patients with viral myocarditis, and to establish the prognostic value of various clinical, functional, and cardiovascular magnetic resonance (CMR) parameters.
Long-term mortality of viral myocarditis, as well as potential risk factors for poor clinical outcome, are widely unknown.
A total of 222 consecutive patients with biopsy-proven viral myocarditis and CMR were enrolled. A total of 203 patients were available for clinical follow-up, and 77 patients underwent additional follow-up CMR. The median follow-up was 4.7 years. Primary endpoints were all-cause mortality and cardiac mortality.
We found a relevant long-term mortality in myocarditis patients (19.2% all cause, 15% cardiac, and 9.9% sudden cardiac death [SCD]). The presence of late gadolinium enhancement (LGE) yields a hazard ratio of 8.4 for all-cause mortality and 12.8 for cardiac mortality, independent of clinical symptoms. This is superior to parameters like left ventricular (LV) ejection fraction, LV end-diastolic volume, or New York Heart Association (NYHA) functional class, yielding hazard ratios between 1.0 and 3.2 for all-cause mortality and between 1.0 and 2.2 for cardiac mortality. No patient without LGE experienced SCD, even if the LV was enlarged and impaired. When focusing on the subgroup undergoing follow-up CMR, we found an initial NYHA functional class >I as the best independent predictor for incomplete recovery (p = 0.03).
Among our population with a wide range of clinical symptoms, biopsy-proven viral myocarditis is associated with a long-term mortality of up to 19.2% in 4.7 years. In addition, the presence of LGE is the best independent predictor of all-cause mortality and of cardiac mortality. Furthermore, initial presentation with heart failure may be a good predictor of incomplete long-term recovery.
本研究旨在评估病毒性心肌炎患者的长期死亡率,并确定各种临床、功能和心血管磁共振(CMR)参数的预后价值。
病毒性心肌炎的长期死亡率以及临床预后不良的潜在危险因素尚不清楚。
共纳入 222 例经活检证实的病毒性心肌炎和 CMR 患者。共有 203 例患者可进行临床随访,77 例患者进行了额外的随访 CMR。中位随访时间为 4.7 年。主要终点为全因死亡率和心脏死亡率。
我们发现心肌炎患者存在较高的长期死亡率(19.2%为全因死亡,15%为心脏死亡,9.9%为猝死[SCD])。迟发钆增强(LGE)的存在使全因死亡率的危险比为 8.4,心脏死亡率的危险比为 12.8,独立于临床症状。这优于左心室(LV)射血分数、LV 舒张末期容积或纽约心脏协会(NYHA)功能分级等参数,全因死亡率的危险比为 1.0 至 3.2,心脏死亡率的危险比为 1.0 至 2.2。没有 LGE 的患者即使 LV 扩大和功能受损也不会发生 SCD。当关注接受随访 CMR 的亚组时,我们发现初始 NYHA 功能分级>I 是不完全恢复的最佳独立预测因子(p = 0.03)。
在我们具有广泛临床症状的人群中,经活检证实的病毒性心肌炎在 4.7 年内的长期死亡率高达 19.2%。此外,LGE 的存在是全因死亡率和心脏死亡率的最佳独立预测因子。此外,心力衰竭的初始表现可能是不完全长期恢复的良好预测因子。